Associated Genetic Biomarkers
NRG4 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains NRG4 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with NRG4 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is NRG4 Expression .
Docetaxel and seribantumab are the most frequent therapies in trials with NRG4 as an inclusion criteria .
Significance of NRG4 in Diseases
Non-Small Cell Lung Carcinoma +
NRG4 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRG4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.